FMR LLC Discloses 6.317% Passive Stake in Arcus Biosciences
Ticker: RCUS · Form: SC 13G · Filed: Feb 9, 2024 · CIK: 1724521
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-stake, SC-13G
TL;DR
**FMR LLC just revealed a 6.317% passive stake in Arcus Biosciences, signaling institutional confidence.**
AI Summary
FMR LLC, a major investment management firm, and its Chair and CEO, Abigail P. Johnson, have reported a significant passive stake of 6.317% in Arcus Biosciences, Inc., totaling 4,728,782 shares of common stock. This filing, dated February 9, 2024, indicates that FMR LLC holds sole voting power over 4,728,058 shares and sole dispositive power over 4,728,782 shares. This matters to investors because a large, passive institutional stake from a firm like FMR can signal confidence in the company's long-term prospects, potentially attracting more institutional interest and providing a stable shareholder base for Arcus Biosciences.
Why It Matters
A major institutional investor like FMR LLC taking a significant passive stake can be seen as a vote of confidence, potentially stabilizing the stock and attracting further institutional investment.
Risk Assessment
Risk Level: low — This filing indicates a passive investment, meaning FMR LLC is not seeking to influence management, which generally poses low risk to existing shareholders.
Analyst Insight
A smart investor would view this as a positive signal, suggesting potential stability and long-term confidence from a major institutional player, and might consider further research into Arcus Biosciences' fundamentals.
Key Numbers
- 4,728,782 — Shares Beneficially Owned (Total common stock shares of Arcus Biosciences held by FMR LLC and Abigail P. Johnson.)
- 6.317% — Percent of Class (The percentage of Arcus Biosciences' common stock owned by FMR LLC and Abigail P. Johnson.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, associated with FMR LLC
- Arcus Biosciences, Inc. (company) — issuer of the securities
- 4,728,782 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 6.317% (dollar_amount) — percentage of class beneficially owned
- February 9, 2024 (dollar_amount) — date of filing
Forward-Looking Statements
- Arcus Biosciences may see increased institutional investor interest due to FMR LLC's significant stake. (Arcus Biosciences, Inc.) — medium confidence, target: Next 6-12 months
FAQ
Who is the primary reporting person in this SC 13G filing?
The primary reporting person in this SC 13G filing is FMR LLC, as stated in Item 1 of the filing.
What is the total number of shares of Arcus Biosciences, Inc. common stock beneficially owned by FMR LLC and Abigail P. Johnson?
FMR LLC and Abigail P. Johnson beneficially own a total of 4,728,782 shares of Arcus Biosciences, Inc. common stock, as reported in Item 4(a) and Item 9 for both reporting persons.
What percentage of Arcus Biosciences, Inc.'s common stock does FMR LLC and Abigail P. Johnson collectively own?
FMR LLC and Abigail P. Johnson collectively own 6.317% of Arcus Biosciences, Inc.'s common stock, as stated in Item 11 for both reporting persons and Item 4(b) for FMR LLC.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as indicated by the checked box in the filing.
What is the CUSIP number for Arcus Biosciences, Inc. common stock mentioned in the filing?
The CUSIP number for Arcus Biosciences, Inc. common stock is 03969F109, as stated in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Arcus Biosciences, Inc. (RCUS).